Novo Nordisk PE Ratio 2006-2019 | NVO

Current and historical p/e ratio for Novo Nordisk (NVO) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novo Nordisk PE ratio as of September 20, 2019 is 21.33.
Novo Nordisk PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-09-20 52.94 22.15
2019-06-30 51.04 $2.39 21.36
2019-03-31 52.31 $2.46 21.26
2018-12-31 46.07 $2.53 18.21
2018-09-30 47.14 $2.52 18.71
2018-06-30 45.68 $2.56 17.84
2018-03-31 48.77 $2.47 19.75
2017-12-31 52.28 $2.32 22.54
2017-09-30 46.91 $2.29 20.48
2017-06-30 41.35 $2.25 18.38
2017-03-31 33.05 $2.26 14.62
2016-12-31 33.89 $2.23 15.20
2016-09-30 39.30 $2.20 17.86
2016-06-30 50.33 $2.11 23.85
2016-03-31 50.71 $1.99 25.48
2015-12-31 53.42 $2.01 26.58
2015-09-30 49.88 $1.92 25.98
2015-06-30 50.36 $1.85 27.22
2015-03-31 49.10 $1.85 26.54
2014-12-31 38.34 $1.73 22.16
2014-09-30 43.14 $1.77 24.37
2014-06-30 41.85 $1.79 23.38
2014-03-31 41.36 $1.76 23.53
2013-12-31 32.86 $1.69 19.40
2013-09-30 30.09 $1.66 18.15
2013-06-30 27.56 $1.58 17.46
2013-03-31 28.72 $1.45 19.81
2012-12-31 28.46 $1.36 20.93
2012-09-30 27.52 $1.27 21.64
2012-06-30 25.35 $1.19 21.33
2012-03-31 24.19 $1.15 21.07
2011-12-31 19.75 $1.11 17.79
2011-09-30 17.05 $1.07 16.00
2011-06-30 21.47 $1.02 21.05
2011-03-31 21.46 $0.95 22.54
2010-12-31 19.01 $0.89 21.26
2010-09-30 16.62 $0.80 20.83
2010-06-30 13.68 $0.75 18.24
2010-03-31 13.02 $0.72 18.14
2009-12-31 10.59 $0.67 15.72
2009-09-30 10.44 $0.65 16.02
2009-06-30 9.03 $0.64 14.03
2009-03-31 7.96 $0.57 13.96
2008-12-31 8.34 $0.55 15.05
2008-09-30 8.31 $0.48 17.31
2008-06-30 10.71 $0.43 24.73
2008-03-31 11.23 $0.33 34.36
2007-12-31 10.39 $0.28 36.98
2007-09-30 9.70 $0.31 30.88
2007-06-30 8.70 $0.28 31.06
2007-03-31 7.25 $0.37 19.60
2006-12-31 6.60 $0.34 19.65
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.697B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $344.174B 14.99
Roche Holding AG (RHHBY) Switzerland $241.683B 0.00
Merck (MRK) United States $212.562B 17.48
Pfizer (PFE) United States $201.220B 11.85
Novartis AG (NVS) Switzerland $197.737B 17.02
AstraZeneca (AZN) United Kingdom $114.317B 22.12
Sanofi (SNY) France $111.209B 13.66
Eli Lilly (LLY) United States $108.824B 20.31
AbbVie (ABBV) United States $105.372B 8.44
GlaxoSmithKline (GSK) United Kingdom $102.412B 12.87
Bristol-Myers Squibb (BMY) United States $81.559B 11.57
Bayer (BAYRY) Germany $68.561B 9.99
H Lundbeck (HLUYY) Denmark $6.721B 9.70